Is asthma curable
Reading File
Finding Sources
Searching PubMed
asthma AND remission
Searching the Web
GINA 2025 asthma remission cure control
Asthma is usually not considered curable, but it can often be controlled so well that a person has few or no symptoms and lives normally.
Some children, and some adults, enter remission: they may have no symptoms and need little or no treatment for years. That is not always a permanent cure, because asthma can return later, especially after viral infections, allergen exposure, smoking/vaping, or other triggers. Recent GINA guidance recognizes remission both on and off treatment, but distinguishes it from permanent elimination of the disease. GINA asthma strategy
What helps most:
- Use the prescribed preventer inhaler, commonly an inhaled corticosteroid
- Keep a reliever inhaler available as directed
- Identify and reduce triggers, such as smoke, allergens, cold air, or workplace exposures
- Use a written asthma action plan and review inhaler technique regularly
- Do not stop preventive treatment abruptly just because you feel well. GINA advises against completely stopping inhaled corticosteroids in most adults and adolescents. GINA summary guide
For severe asthma, biologic treatments can lead some people to clinical remission, but this generally means excellent control while treatment continues rather than a proven permanent cure. A 2025 systematic review examined remission with biologics (PMID: 39549709).
Seek urgent care if you are severely short of breath, struggling to speak full sentences, becoming drowsy/confused, or your reliever inhaler is not helping.
Find the latest guidelines on asthma remission and treatment
Reading File
Reading File
Finding Sources
Searching PubMed
asthma AND remission
Searching PubMed
asthma AND guideline
Searching the Web
site:ginasthma.org GINA 2026 Strategy Report asthma remission treatment PDF
Searching the Web
site:nhlbi.nih.gov asthma guidelines treatment 2020 focused updates
Reading Web Page
https://ginasthma.org/wp-content/uploads/2026/05/GINA-2026-S…
Reading File
Reading Article
PMID: 39549709
Latest major asthma guidance
The most current global guidance is the GINA 2026 Strategy Report, published 5 May 2026. It covers diagnosis, day-to-day treatment, stepping treatment up or down, severe asthma, and asthma remission. GINA’s 2026 report page provides the official documents.
For the United States, the latest NHLBI/NAEPP update remains the 2020 Focused Updates, which supplement rather than fully replace the 2007 guideline. NHLBI’s guideline page is the official source.
What the 2026 GINA guideline says about remission
GINA now recognizes that asthma can enter remission, but does not describe asthma as universally curable.
- Clinical remission generally means no or minimal symptoms, no exacerbations, no need for oral corticosteroids, and stable or improved lung function over a defined prolonged period.
- Complete remission additionally considers normalization of airway hyperresponsiveness and/or inflammatory markers.
- Remission may occur on treatment, particularly in some people with severe asthma receiving biologic therapy, or off treatment.
- Criteria are not yet standardized. A 2025 systematic review found substantial variation in definitions; among severe-asthma patients receiving biologics, pooled clinical-remission estimates were about 38% using a 3-component definition and 30% using a 4-component definition that included lung function. Shackleford et al., 2025, PMID: 39549709
Even when remission is achieved, GINA advises clinicians to reassess treatment carefully rather than assuming the disease has permanently disappeared.
Current treatment approach for adults and adolescents
1. Everyone should receive ICS-containing treatment
GINA recommends against treating asthma with a short-acting beta-agonist (SABA, such as albuterol/salbutamol) alone. Treatment should include an inhaled corticosteroid (ICS), because it reduces exacerbations and asthma-related risk.
2. Preferred pathway: Track 1
GINA’s preferred option uses low-dose ICS-formoterol as the reliever across treatment steps. It is called an anti-inflammatory reliever because it combines rapid symptom relief with anti-inflammatory medication.
| GINA step | Usual Track 1 approach |
|---|---|
| Steps 1-2 | As-needed low-dose ICS-formoterol |
| Step 3 | Low-dose maintenance ICS-formoterol plus the same inhaler as needed, called MART |
| Step 4 | Medium-dose maintenance ICS-formoterol plus the same inhaler as needed, called MART |
| Step 5 | Specialist assessment, phenotype evaluation, and add-on treatment for severe asthma |
GINA prefers this track because it reduces severe exacerbations compared with SABA-reliever regimens while achieving similar symptom control and lung function. GINA 2026 Strategy Report
3. Alternative pathway: Track 2
If ICS-formoterol is unavailable or unsuitable, an alternative uses regular ICS-containing maintenance therapy with an ICS-SABA reliever, or a SABA reliever where needed. This route depends strongly on reliable daily use of the controller inhaler. A person using SABA frequently or having attacks needs review of diagnosis, inhaler technique, adherence, triggers, and treatment intensity.
4. Severe or difficult-to-treat asthma
Before labeling asthma as severe, GINA recommends checking:
- Whether the diagnosis is correct
- Inhaler technique and adherence
- Tobacco/vape exposure and relevant triggers
- Coexisting conditions such as obesity, chronic rhinosinusitis/nasal polyps, reflux when symptomatic, anxiety/depression, and sleep apnea
- Whether the person has an asthma phenotype that may respond to targeted treatment
For persistent uncontrolled asthma despite optimized high-dose ICS-LABA treatment, specialist-directed options include biologics targeting Type 2 inflammation, such as anti-IgE, anti-IL-5/IL-5R, anti-IL-4Rα, and anti-TSLP treatments. GINA emphasizes reducing and, where possible, avoiding long-term oral corticosteroids because of their adverse effects. GINA severe-asthma guide
Stepping down treatment in remission or good control
When asthma has been well controlled for 2-3 months, GINA recommends considering a gradual reduction to identify the lowest effective treatment level.
Before reducing treatment:
- Avoid doing it during a respiratory infection, travel, or pregnancy.
- Review prior severe attacks, emergency visits, and lung function.
- Record current symptom control and lung function where possible.
- Provide or update a written asthma action plan and arrange follow-up.
A typical approach is to lower the maintenance ICS dose by 25-50%, then reassess after 2-3 months before another reduction. Adults and adolescents should not completely stop ICS-containing treatment solely because they feel well. GINA 2026 Summary Guide
For severe asthma responding well to biologics, GINA suggests reassessing medicines every 3-6 months. If treatment is reduced, oral corticosteroids are usually addressed first, with appropriate monitoring for adrenal insufficiency. ICS-containing treatment should generally continue.
Important practical points
- Have a personalized written asthma action plan.
- Review inhaler technique at every visit.
- Check symptom control and exacerbation risk separately. Few symptoms do not always mean low risk of a serious attack.
- Seek urgent care for severe breathlessness, trouble speaking full sentences, blue/gray lips, drowsiness/confusion, or failure to improve after reliever medication.
Treatment selection, inhaler choice, and dose should be individualized by a clinician, especially for children, pregnancy, heart disease, or frequent exacerbations.
This is a shared conversation. Sign in to Orris to start your own chat.